So if I’m interpreting this correctly … even when they’re initially giving away the BlastX free for the trial phase, the margin on the Collagen makes the combined sale to Medicare profitable? Is that how others read this?
Ann: Next Science US Medicare accreditation signals growth, page-2
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.040(11.4%) |
Mkt cap ! $113.7M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 39.0¢ | 36.0¢ | $8.625K | 22.34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 1501 | 1 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
38.5¢ |
Change
0.040 ( 13.2 %) |
||||
| Open | High | Low | Volume | ||
| 37.5¢ | 38.5¢ | 37.5¢ | 5905 | ||
| Last updated 15.44pm 09/05/2024 ? | |||||
| NXS (ASX) Chart |